Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04119115 · ClinicalTrials.gov registry record
Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
A clinical trial, sponsored by Corewell Health East.
- Terminated
- Registry status
- 28
- Enrollment target
NCT04119115: Clinical Trial study, sponsored by Corewell Health East.
NCT04119115 is a clinical trial that was terminated before completion, run by Corewell Health East. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04119115 was terminated before completion, sponsored by Corewell Health East.
- TERMINATED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if combining a state-of-the-art form imaging modality with metabolomics in different types of Interstitial Lung Diseases (ILD) patients compared to controls with chronic obstructive pulmonary disorder (COPD)/emphysema and healthy controls will be a better predictor of disease progression. ILD's are a group of chronic, progressive lung diseases. The most common ILD is idiopathic pulmonary fibrosis (IPF). Metabolomics provides a "snapshot" in time of all metabolites present in a biological sample. The imaging procedure should take approximately 20 minutes. All study related collections of samples will be done in a single visit if possible. There are no direct benefits to participants. This is not a treatment study.
Primary Outcome
CT-V scores between inhalation and exhalation will be calculated at a voxel level on each lung using the "Integrated Jacobian Formulation" (IJV) CT-V method in patients with IPF, non-IPF ILD and COPD/emphysema patients. Several factors, including the volume of identified "cold spots" (areas with decreased ventilation), total ventilation (the integral of CT-V image over the whole lung), and texture analytics (local means, variances, etc.) will be used to define a CT-V pulmonary function metric. T
Interventions
- DEVICE CT-V
- OTHER Metabolites
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2022-10-20 |
Why NCT04119115 stopped before completion
NCT04119115 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which CT-V is the first listed.
NCT04119115 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04119115 about?
NCT04119115 is a clinical study titled "Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases". The purpose of this study is to find out if combining a state-of-the-art form imaging modality with metabolomics in different types of Interstitial Lung Diseases (ILD) patients compared to controls with chronic obstructive pulmonary disorder (COPD)/emphysema and healthy controls will be a better pre...
What is the current status of trial NCT04119115?
This trial is currently terminated. The enrollment target is 28 participants. The study started on 2021-09-30. Estimated completion is 2022-10-20.
What interventions are being tested in trial NCT04119115?
The interventions under investigation include: CT-V (DEVICE), Metabolites (OTHER).
Who is sponsoring clinical trial NCT04119115?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI